Jazz Pharmaceuticals plc JAZZ

NAS: JAZZ | ISIN: IE00B4Q5ZN47   30/04/2025
116,96 USD (+0,47%)
(+0,47%)   30/04/2025

30 april 2025 · Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference · Persbericht

25 april 2025 · Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer · Persbericht

23 april 2025 · Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma · Persbericht

22 april 2025 · Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025 · Persbericht

21 april 2025 · Jazz Pharmaceuticals Completes Acquisition of Chimerix · Persbericht

26 maart 2025 · Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference · Persbericht

19 maart 2025 · Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting · Persbericht

5 maart 2025 · Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio · Persbericht

9 september 2024 · Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024 · Persbericht

5 september 2024 · Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024 · Persbericht

4 september 2024 · Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases · Persbericht

3 september 2024 · Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases · Persbericht

22 augustus 2024 · Jazz Pharmaceuticals Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies · Persbericht

21 augustus 2024 · Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences · Persbericht

31 juli 2024 · Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance · Persbericht

25 juli 2024 · Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting · Persbericht

22 juli 2024 · Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026 · Persbericht

17 juli 2024 · Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024 · Persbericht

9 juli 2024 · Jazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer · Persbericht

20 juni 2024 · Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor · Persbericht

Mijn selecties